- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04436250
ESKETamine for FIBromyalgia Treatment (ESKEFIB)
Intravenous Infusions of S-KETAMINE in Fibromyalgia Syndromes: an Exploratory Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean-Paul Lechat, MD
- Phone Number: 4071 00 32 71 10
- Email: jean-paul.lechat@ghdc.be
Study Contact Backup
- Name: Zuzana Javorcikova, MD
- Phone Number: 1109 00 32 474 64
- Email: z.javorcikova.pro@gmail.com
Study Locations
-
-
Hainaut
-
Gilly, Hainaut, Belgium, 6060
- Recruiting
- Grand Hôpital de Charleroi
-
Contact:
- Zuzana Javorcikova, MD
- Phone Number: 1109 00 32 474 64
- Email: z.javorcikova.pro@gmail.com
-
Contact:
- Jean-Paul Lechat, MD
- Phone Number: 4071 00 32 71 10
- Email: jean-paul@ghdc.be
-
Sub-Investigator:
- Philippe Van der Linden, MD, PhD
-
Sub-Investigator:
- Michel Dangoisse, MD
-
Sub-Investigator:
- Stéphane Nikis, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients suffering from chronic pain (as defined by International Association for the Study of Pain) being diagnosed as fibromyalgia according to the American College of Rheumatology 2016 criteria
- patients qualified for the treatment by S-ketamine as established by our latest clinical practice
- patients aged 18-65 years old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Placebo
Clonidine at a dose of 1 microg/kg Magnesium sulfate at a dose of 40 mg/kg
|
The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
|
Experimental: S-Ketamine Low dose
S-Ketamine at a dose of 0.2 mg/kg
|
The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
|
Experimental: S-ketamine High dose
S-ketamine at a dose of 0.4 mg/kg
|
The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome is twofold, aiming on one side pain relief and on the other the improvement of the patient's functional status
Time Frame: 12 weeks
|
Pain relief will be considered as a two point decrease on the Brief Pain Inventory (BPI) pain severity index at twelve weeks follow-up. (Two points being established as the Minimal Clinically Important Difference (MCID) for fibromyalgic patients). The functional status will be evaluated by the BPI Interference scale. An improvement will be considered as a one point reduction on this index (as established by the MCID). The primary outcome is to determine whether the association of S-ketamine to the analgesic treatment will increase the number of patients showing a clinically significant improvement of pain and/or functional status. |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients showing 50 % reduction in the BPI (Brief Pain Inventory) pain index
Time Frame: 12 weeks
|
Measures will be done with different questionnaires
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean-Paul Lechat, MD, Grand Hôpital de Charleroi
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Fibromyalgia
- Myofascial Pain Syndromes
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Psychotropic Drugs
- Antidepressive Agents
- Ketamine
- Esketamine
Other Study ID Numbers
- ESKEFIB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
Clinical Trials on Active comparator
-
TiumBio Co., Ltd.RecruitingEndometriosisCzechia, Italy, Russian Federation, Poland, Ukraine
-
Stanford UniversityRecruitingTreatment Resistant Depression | Bipolar II Disorder, Most Recent Episode Major Depressive | Current Depressive EpisodeUnited States
-
Eisai Inc.CompletedAlzheimer's DiseaseUnited States
-
United States Naval Medical Center, San DiegoTerminatedPTSD - Post Traumatic Stress Disorder
-
Case Western Reserve UniversityHighland Instruments, Inc.Recruiting
-
Eisai Inc.CompletedHealthy | Drug AbuseCanada
-
Cognition TherapeuticsRecruitingAge-Related Macular DegenerationUnited States
-
AnchorDx Medical Co., Ltd.Peking University First Hospital; Peking Union Medical College Hospital; Peking... and other collaboratorsRecruitingUpper Tract Urothelial CarcinomaChina
-
Case Western Reserve UniversityHighland Instruments, Inc.RecruitingDiabetic Neuropathies | Chronic PainUnited States
-
Medical University InnsbruckBarmherzige Brüder Vienna; Tiroler Landeskrankenanstalten GmbH (TILAK); Tiroler... and other collaboratorsCompletedStroke | Ischemic Attack, Transient | Cost-Benefit Analysis | Secondary Prevention | Disease ManagementAustria